Onco360 to distribute two new GSK cancer drugs

Specialty pharmacy joins limited distribution network for Tafinlar, Mekinist

NEW YORK — Onco360 is joining the limited-distribution network for two newly approved cancer drugs made by GlaxoSmithKline, the specialty pharmacy company said.

The New York-based company said it had been selected as a distributor of Tafinlar (dabrafenib) and Mekinist (trametinib). The drugs were approved as standalone therapies, not a combined therapy.

"I'm proud that GSK continues to select our organization as a pharmacy provider for their limited-distribution products," Onco360 CEO Burt Zweigenhaft said. "Onco360 is the comprehensive and trusted source for oncology pharmaceutical needs, and we are dedicated to advancing the continuum of pharmaceutical cancer care."

 

Login or Register to post a comment.